Multistem from Angiotech, Athersys benefits heart attack patients

09/24/2010 | Reuters

Angiotech Pharmaceuticals and Athersys said a Phase I trial showed that MultiStem, their experimental stem cell treatment, proved to be effective in improving cardiac function and was well-tolerated by heart attack patients who were given different dosages. The companies said they plan to conduct trials next year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY